ArticleJournal of menopausal medicine2016
Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels.
Article in Journal of menopausal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The association between circulating irisin levels and osteoporosis in women: a systematic review and meta-analysis of observational studies.Frontiers in endocrinology · 2024Pooled it
- Association of Chemerin, follicle stimulating hormone, lipid profiles, and cardiometabolic indices with the premature ovarian insufficiency.Scientific reports · 2026Article
- Bifurcate Regulation of Hematopoietic Homeostasis and Bone Osteogenesis by VHL-HIF2α-Controlled Adipocyte Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Role and Validation of Lactylation-Related Gene Markers in Postmenopausal Osteoporosis.Applied biochemistry and biotechnology · 2025Article
- Irisin: A Multifaceted Hormone Bridging Exercise and Disease Pathophysiology.International journal of molecular sciences · 2024Review
- Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia.Biomedicines · 2024Review
- The role of adipokines in osteoporosis management: a mini review.Frontiers in endocrinology · 2024Review
- The Role of Irisin throughout Women's Life Span.Biomedicines · 2023Review
- Serum Irisin level is associated with fall risk, muscle strength, and cortical porosity in postmenopausal women.Frontiers in endocrinology · 2023Article
- Role of irisin in bone diseases.Frontiers in endocrinology · 2023Review
- Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature.Journal of clinical medicine · 2022Review
- Association of serum levels of Visfatin, Intelectin-1, RARRES2 and their genetic variants with bone mineral density in postmenopausal females.Frontiers in endocrinology · 2022Article
- Association of High Serum Chemerin with Bone Mineral Density Loss and Osteoporotic Fracture in Elderly Chinese Women.International journal of women's health · 2022Article
- Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females.Frontiers in pharmacology · 2022Article
- Irisin at the crossroads of inter-organ communications: Challenge and implications.Frontiers in endocrinology · 2022Review
- Role of the Myokine Irisin on Bone Homeostasis: Review of the Current Evidence.International journal of molecular sciences · 2021Review
- Irisin Has a Protective Role against Osteoporosis in Ovariectomized Rats.BioMed research international · 2021Article
- Is grand multiparity a risk factor for the development of postmenopausal osteoporosis?Clinical interventions in aging · 2018Article
- Association of serum chemerin with calcium, alkaline phosphatase and bone mineral density in postmenopausal females.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objective of this study was to describe the levels of chemerin, irisin and apolipoprotein M (apoM) in women with postmenopausal osteoporosis.
methodsThe study included 88 women with postmenopausal osteoporosis. Based on World Health Organization criteria, women with a T-score of ≤ -2.5 were defined as osteoporotic. In this case-control study, postmenopausal women with T-score > -1 were selected as controls (n = 88) and case-matched in a 1:1 ratio based on age (within 2 years) and body mass index (BMI) (within 1.0 kg/m(2)). ApoM, irisin and chemerin levels were determined by a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
resultsThere were no significant differences in age, BMI, parity, cholesterol and apoM levels between the two groups. C-reactive protein levels were significantly increased in women with osteoporosis. Serum chemerin levels (240.1 ± 46.1 vs. 261.5 ± 50.8 ng/mL) were significantly lower in the women with osteoporosis, as compared to the controls (P = 0.004). Serum irisin levels were also decreased in women with osteoporosis (0.7 ± 0.2 vs. 0.8 ± 0.2 ng/mL; P = 0.007).
conclusionIn the present study, osteoporosis was associated with decreased levels of circulating chemerin and irisin. These findings suggested that adipokines might play a role in the pathogenesis of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.